Banyan Biomarkers is developing the first objective blood test that may rule out the need for CT scans in patients with suspected mild traumatic brain injury.
Capping off a great 2018, Banyan’s BTI test for traumatic brain injury has earned a spot on @CONNECTinSD’s annual list of “most innovative” products. Check out @Xconomy’s coverage of all 7 winners here: https://t.co/aYo2fqj6nX #CONNECTMIP#diagnostics#TBI
FDA Grants Marketing Authorization to Banyan Biomarkers for the First Diagnostic Blood Test for #TraumaticBrainInjury https://t.co/ABQJrgk02A
#TBI#Concussion